CTL | G0 (0–2 months) | G3 (2–4 months) | G6 (5–8 months) | G12 (9–16 months) | |
Total | n=8 | n=15 | n=20 | n=18 | n=23 |
CMV-UT | – | n=6 | n=9 | n=10 | n=9 |
CMV-VAL | – | n=9 | n=11 | n=8 | n=14 |
Note: The fact that not all the study subjects could be included longitudinally in all time points explains the heterogeneous numbers within the groups in tables 1A and 1B.
CTL, control; G, group; UT, untreated; VAL, valganciclovir.